Antimicrobial Drugs: Recent Breakthroughs Provide Positive News, Yet We Is Losing the Bigger Battle

During a tenure as head of the World Health Organization, a former leader famously remarked that all of the “easy” antibiotics had already been found. The argument was that in tackling the pressing threat of antibiotic-resistant bacterial infections, we would face difficulties to find new treatments – or conserve the existing ones – without finding novel approaches of operating. This assessment proved correct.

A Sluggish and Unprofitable Pipeline

Since the late 2010s, just 16 antibiotics have gained broad regulatory approval – mostly close relatives of medicines already in use and thus unlikely to overcome resistance for long. The creation of new ones is a lengthy and financially unattractive endeavor, given that curative treatments are less lucrative as those managing chronic conditions. The overall prospect continues to be grim.

A Spark of Hope and a Novel Approach

Nevertheless, the recent announcement of a pair of novel regulator-approved antibiotics against gonorrhoea is a welcome development and, crucially, confirms a innovative method of incentivising research. A particular of the new drugs, Zoliflodacin, is the product of a unique type of partnership between a global health organization and a drug firm. The public health partnership provided financial support and organised testing phases to offset costs and clear regulatory hurdles. This type of support in advance helps direct the sector towards areas of greatest global need.

This model and another lauded revenue guarantee scheme – launched to ensure income to firms investing in specific antibiotics – represent the best hope of sustaining a dripfeed of novel treatments from the existing system.

The Unavoidable Challenge of Resistance

But even hurrying the development of drugs currently in development is not sufficient. Zoliflodacin is at times categorized as a new class of antimicrobial, indicating it targets a part of the infectious bacteria that no other drug does, theoretically forcing the pathogen to begin anew in developing a defense to it. Scientists and physicians are relieved to have a new drug for gonorrhoea – which has strains resistant to all existing treatments – but warn that eventual drug resistance to it is certain.

As has grown customary with new antibiotics, there is therefore an debate about whether it should be held in reserve, restricted to extremely drug-resistant cases only – confining its use to settings where high‑end lab testing is accessible. This kind of prudent approach should be the worldwide norm, but frequently can't be deployed readily in many regions.

A Dwindling Pipeline of Innovation

On a wider scale, it is difficult to see where the stream of additional novel antimicrobials we need could realistically originate. The former official's statement nodded to the fact that surveying the natural world for biological compounds – as with the first antibiotic – has had diminishing returns. Use of artificial intelligence has been proposed to accelerate the search, although a much-celebrated initial discovery identified in 2020 has not yet progressed past preclinical studies. Fully lab-created compounds, that are largely or entirely synthesized, are constantly in development, but often run up against the iron laws of molecular science – just because we imagine a compound does not guarantee we can create it easily.

Running Fast to Stay in Place

The dominant expert assessment is that when it comes to antibiotics, we must move with great speed truly just to stay in the same place. Prudent, internationally coordinated use is the sole method to preserve our therapeutic edge. Regrettably, the scale of forthcoming breakthroughs is going to seem miserly compared with the curative bonanza of the previous century.